Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
Publication Type:
Journal Article
Authors:
Yin Ren, Jessica E. Sagers, Lukas D. Landegger, Sangeeta N. Bhatia, and Konstantina M. Stankovic
Source:
Scientific Reports, Volume 7, Issue 1 (2017)
URL:
http://www.nature.com/articles/s41598-017-13032-9
Abstract:
Vestibular schwannoma (VS) is the most common tumor of the cerebellopontine angle, and it typically presents with sensorineural hearing loss. The genomic landscape of schwannoma is complex and many of the molecules implicated in VS pathogenesis represent targets not amenable to antibody-based or small molecule therapeutics. Tumor-targeted delivery of small interfering RNA (siRNA) therapeutics provides a direct and effective means to interrogate targets while minimizing off-target effects. To establish a preclinical model for therapeutic inhibition of putative targets in VS, archived tumor specimens, fresh tumor cells derived from patients with sporadic VS, and an established schwannoma cell line were screened. Nanoparticles directed by the tumor-homing peptide iRGD were selectively taken up by primary VS cultures in vitro via interactions with alphav, beta3, beta5 integrins and neuropilin-1 (NRP-1). Cellular uptake was inhibited by a neutralizing antibody against alpha v integrin in a dose-dependent manner. When applied to primary VS cultures, iRGD-targeted nanoparticles delivered siRNA directed against TNFalpha; in a receptor-specific fashion to potently silence gene expression and protein secretion. Taken together, our results provide a proof of principle for tumor-targeted, nanoparticle-mediated delivery of siRNA to VS and establish a novel platform for the development and pre-clinical screening of molecular therapeutics against VS.
